Compare PKE & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | LBRX |
|---|---|---|
| Founded | 1954 | 2015 |
| Country | United States | United States |
| Employees | 125 | 27 |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.7M | 889.0M |
| IPO Year | 1994 | N/A |
| Metric | PKE | LBRX |
|---|---|---|
| Price | $37.51 | $33.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $46.60 |
| AVG Volume (30 Days) | ★ 412.0K | 313.5K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ 93.10 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $68.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.23 | $13.40 |
| 52 Week High | $39.55 | $33.47 |
| Indicator | PKE | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.05 | 68.47 |
| Support Level | $31.16 | $26.75 |
| Resistance Level | $38.20 | $33.47 |
| Average True Range (ATR) | 2.01 | 1.79 |
| MACD | 0.57 | 0.39 |
| Stochastic Oscillator | 73.09 | 89.89 |
Park Aerospace Corp is an aerospace company that develops and manufactures composite materials used to produce composite structures for the aerospace market. Its products include film adhesives, lightning strike protection materials, specialty ablative materials for rocket motors and nozzles, and materials for radome applications. The Company offers composite materials designed for hand lay-up and automated fiber placement (AFP) manufacturing applications, which are used in jet engines, large and regional transport aircraft, military aircraft, unmanned aerial vehicles (UAVs), business jets, general aviation aircraft, and rotary wing aircraft. It operates in North America, Asia, and Europe, with North America generating maximum revenue.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.